GenTel Looks to Stake Claim in Multiplexed Coagulation Market; New Assay Due in Q1 | GenomeWeb

SAN DIEGO -- With a new name and an old partner, GenTel BioSciences expects to roll out a multiplex immunoassay for coagulation research later this quarter, hoping to play in an underpopulated niche market and prove itself as a catalog array provider.

The announcement comes at a time when GenTel is repositioning itself from a slide and microplate company to one that offers content arrays. The company, formerly GenTel BioSurfaces, renamed itself earlier this month to reflect this change (see BAN 1/10/2006).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.